The Use of Neurotoxins for Palliative Treatment of Chronic Joint Pain
Reference61 articles.
1. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated projected prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation among US adults, 2015-2040. Arthritis & Rhematology. 2016;68(7):1582-1587
2. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis and Rheumatism. 2006;54(1):226-229
3. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nature Reviews Rheumatology. 2013;9(11):654-664
4. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis and Cartilage. 2013;21(9):1145-1153
5. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Osteoarthritis and absenteeism costs: Evidence from US National survey data. Journal of Occupational and Environmental Medicine. 2010;52(3):263-268